AI assistant
Sending…
BIOMARIN PHARMACEUTICAL INC — Proxy Solicitation & Information Statement 2024
Apr 9, 2024
30583_rns_2024-04-09_6cbb20ce-7066-45fe-ad01-3346acf45401.zip
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
DEFA14A 1 a2024biomarinproxystatemen.htm DEFA14A Document created using Wdesk Copyright 2024 Workiva Document
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )
☑ Filed by the Registrant ☐ Filed by a party other than the Registrant
| CHECK THE APPROPRIATE BOX: | |
|---|---|
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☑ | Definitive Additional Materials |
| ☐ | Soliciting Material under §240.14a-12 |
BioMarin Pharmaceutical Inc.
(Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
| PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY): | |
|---|---|
| ☑ | No fee required |
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
More from BIOMARIN PHARMACEUTICAL INC
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 4
Interim / Quarterly Report
2026
May 5
Report Publication Announcement
2026
May 4
M&A Activity
2026
Apr 27
M&A Activity
2026
Apr 23
Annual Report
2026
Apr 21
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 19